$TSOI Therapeutic Solutions International Files Patent on Ability of QuadraMune Ingredient Pterostilbene to Reduce Inflammation while Stimulating Brain Protective Biological Pathways
Mechanistic Studies Continuing on QuadraMune™ a COVID19 Candidate in Clinical Trial

Company Continues Quest to Dominate Intellectual Property Regarding COVID-19 Associated Pathologies

NEWS PROVIDED BY

Therapeutic Solutions International
Jul 28, 2020, 09:45 ET
https://www.prnewswire.com/news-releases/ther...01258.html